Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

Collection UNKNOWN
R. Ogutu, Bernhards; J. Apollo, Odika; McKinney, Denise; Okoth, Willis; Siangla, Joram; Dubovsky, Filip; Tucker, Kathryn; Waitumbi, John N.; Diggs, Carter; Wittes, Janet; Malkin, Elissa; Leach, Amanda; A. Soisson, Lorraine; B. Milman, Jessica; Otieno, Lucas; A. Holland, Carolyn; Polhemus, Mark; A. Remich, Shon; F. Ockenhouse, Christian; Cohen, Joe; Ripley Ballou, W.; K. Martin, Samuel; Angov, Evelina; Ann Stewart, V.; A. Lyon, Jeffrey; Gray Heppner Jr, D.; R. Withers, Mark;
  • Publisher: Figshare
  • Related identifiers: doi: 10.1371/journal.pone.0004708
  • Subject: Biotechnology | confers | antigen-specific | antibody | concentrations | children | Cancer | malaria | eliciting | kenya
    mesheuropmc: parasitic diseases

<div><h3>Objective</h3><p>The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-terminal fragment of merozoite surface protein-1 (MSP-1) of the 3D7 clone of <em>P. falciparum</em>. Formulated with AS02 (a proprietary Adjuvant System), it constitutes ... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection)
  • Cite this research product